Loading...
NPI 1174964738 · El Monte, CA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Fulgent Therapeutics, LLC. is a clinical medical laboratory provider located in El Monte, California. This profile covers 6 Medicare and 33 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Fulgent Therapeutics, LLC. |
| Address | 4399 Santa Anita Ave |
| City | El Monte |
| State | CA |
| ZIP | 91731 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | July 11, 2013 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $84.9M |
| Medicare | $266.3K |
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
6 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 2,590 | $70 | $191.3K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 2,570 | $30 | $64.2K |
| 87426 | The lab analyst performs an immunoassay to qualitatively or semiquantitatively evaluate the patient blood specimen for antigens of severe acute respiratory syndrome coronavirus such as SARS–CoV–2,… | 270 | $40 | $9.3K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 50 | $50 | $2.3K |
| 0013A | N/A | 30 | $50 | $1.2K |
| 0003A | N/A | 20 | $50 | $720 |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 6 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
33 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 1,237,210 | $50 | $65.6M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 704,250 | $10 | $7.7M |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 330,780 | $20 | $5.6M |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 58,240 | $90 | $5.2M |
| 87426 | The lab analyst performs an immunoassay to qualitatively or semiquantitatively evaluate the patient blood specimen for antigens of severe acute respiratory syndrome coronavirus such as SARS–CoV–2,… | 9,570 | $30 | $248.9K |
| 81479 | Use 81479 to report a molecular pathology procedure that does not have a specific code. | 710 | $130 | $91.1K |
| 81406 | The lab analyst performs the technical lab test to complete one of the specific genetic analyses listed in this Tier 2, Level 7 molecular pathology code. | 560 | $110 | $61.2K |
| 81329 | The lab analyst performs the technical lab test to detect deletions in the survival of motor neuron 1 (SMN1), telomeric, gene and may also analyze the survival of motor neuron 2 (SMN2), centromeric,… | 610 | $40 | $22.7K |
| 81222 | The lab analyst performs the technical lab test to analyze specific changes involving repeated or deleted nucleotides in the cystic fibrosis transmembrane conductance regulator gene, also known as… | 530 | $40 | $19.2K |
| 0003A | N/A | 610 | $20 | $12.8K |
Showing 1–10 of 33
How this provider's Medicaid billing volume and revenue compare to other California providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. California median
33 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 81443 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen for genetic sequences of at least 15 genes, such as the 20 gene examples listed in the code descriptor. The… | 8 | 10 | 3,040 | $290 | $4.7M |
| 81361 | The lab analyst performs the technical lab test to detect the presence of specific changes in the hemoglobin, subunit beta (HBB) gene specifically for common variants, such as HbS, HbC, HbE. | 7 | 10 | 900 | $30 | $1.9M |
| 81220 | The lab analyst performs the technical lab test to detect the presence of changes in the gene for cystic fibrosis transmembrane conductance regulator, also known as CFTR. The test evaluates the CFTR… | 83 | 110 | 190 | $140 | $1.6M |
| 81479 | Use 81479 to report a molecular pathology procedure that does not have a specific code. | 20 | 50 | 500 | $160 | $1.1M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 2 | 750 | 950 | $50 | $890K |
| 81257 | The lab analyst performs the technical lab test to detect the presence of specific changes and possible deleted nucleotides in the alpha globin 1 and alpha globin 2 genes, also known as HBA1/HBA2,… | 10 | 10 | 1,960 | $20 | $830.3K |
| 81329 | The lab analyst performs the technical lab test to detect deletions in the survival of motor neuron 1 (SMN1), telomeric, gene and may also analyze the survival of motor neuron 2 (SMN2), centromeric,… | 22 | 60 | 400 | $40 | $748.5K |
| 81251 | The lab analyst performs the technical lab test to detect the presence of specific changes in the gene for glucosidase, beta, acid, also known as GBA. | 6 | 10 | 770 | $10 | $501.5K |
| 81200 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for aspartoacylase, also known as ASPA. | 6 | 10 | 470 | $10 | $418.1K |
| 81255 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for hexosaminidase A [alpha polypeptide], also known as HEXA. | 7 | 10 | 440 | $10 | $377.9K |
Showing 1–10 of 33
Other providers in the same ZIP code as Fulgent Therapeutics, LLC., ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Altamed Health Services Corp | CA | Federally Qualified Health Center (FQHC) | $0 | $56.2M |
| Sun Clinical Laboratories | CA | Clinical Medical Laboratory | $4M | $8.2M |
| Yan Ping Zhang | CA | Internal Medicine Physician | $1.7M | $0 |
| Cytometry Specialists, Inc. | CA | Clinical Pathology/Laboratory Medicine Physician | $622.5K | $0 |
| Ebram Abdelmalak | CA | Foot & Ankle Surgery Podiatrist | $351.8K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.